Which country did Asciminib come from?

Asciminib (Asciminib) is a drug used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), with the trade name Scemblix. It was approved for medical use in the United States in October 2021 and in the European Union in August 2022. Aceminib is a protein kinase inhibitor, and the most common adverse reactions include upper respiratory tract infection, musculoskeletal pain, fatigue, nausea, rash, and diarrhea.

Aceminibis a novel tyrosine kinase inhibitor (TKI) that specifically targets the myristoyl pocket. It has enhanced selectivity and potent activity against BCR-ABL1 and mutants that most commonly prevent ATP binding competitive inhibitor activity. Clinical trial results in patients with chronic myelogenous leukemia who received two or more TKIs (randomized controlled bosutinib) or had the T315I mutation (single-arm study) showed high levels of activity and a favorable toxicity profile. Its approval provides new options for patients with characteristics of these diseases.

The original drug of Asiminib has not yet been launched in China, so it cannot be included in the medical insurance. The original drug of Asiminib sold overseas is very expensive. The price of 20mg*60 oral tablets is about more than 20,000 US dollars, which is about 150,000 yuan in RMB. There are also Assimini generic drugs produced and marketed overseas, and their drug ingredients are basically the same as those of the original drug. For example, the price of 40mg*60 tablets produced by a Laos pharmaceutical factory may be more than 4,000 yuan per box (the price may fluctuate due to exchange rates). The price is relatively cheap. For more information about overseas drugs and specific prices, please consult Yaode Medical Consultant.